Dr. Vaishampayan on FGFR inhibitors and genetic testing in bladder cancer


Ulka Nitin Vaishampayan, MBBS, discusses the FGFR inhibitor erdafitinib (Balversa) and the importance of genetic/genomic testing in bladder cancer.

Erdafitinib is approved by the FDA for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy. Vaishampayan stresses how it is crucial that patients with bladder cancer receive genetic testing to determine their eligibility for this treatment should they progress on first-line chemotherapy.

Vaishampayan is director, Phase I Program, Rogel Cancer Center, Michigan Medicine, and professor of Internal Medicine, University of Michigan.

Related Videos
Veda Giri, MD, answers a question during a Zoom video interview
Genetic testing for prostate cancer | Image credit: © ktsdesign - stock.adobe.com
DNA molecules
DNA strand illustration
illustration of double helix
illustration of DNA molecule
Related Content
© 2023 MJH Life Sciences

All rights reserved.